The GLP-1 agonists market report provides insights around existing treatment practices in patients with Glucagon-like Peptide-1 (GLP-1) Agonists, approved (if any) and emerging Glucagon-like Peptide-1 (GLP-1) Agonists, market share of individual therapies, patient pool eligible for treatment with Glucagon-like Peptide-1 (GLP-1) Agonists, along with current and forecasted 7MM Glucagon-like Peptide-1 (GLP-1) Agonists market size from 2020-2034 by therapies and by indication
Due to fluctuations in oestrogen (which plays a key role in preserving muscle and bone mass) levels that we see in line with menopausal changes, (peri)menopausal women are already at risk of muscle loss, and 'losing weight by whatever means could reduce bone and muscle mass further, so it is important that someone taking this medication tries to optimise their diet and physical activity levels as much as possible.' Best exercises to prevent muscle loss on GLP-1s Strength training The most effective protection is resistance and strength training, says Dr Ajaz
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey
Anecdotally, we can see that the rebound hunger is stronger when you stop suddenly versus tapering, Anekwe says
If you need significant weight loss results comparable to what tirzepatide before and after outcomes deliver, a probiotic is not going to provide that level of impact
Some trials have reported improvements in power output and aerobic capacity, whereas others have found no significant effect
